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Mr D. aged 39 suffers from a cerebral palsy. The indication of
botulinum toxin injections is retained to a clinical associating
bilateral equinovarus and spasticity of both triceps surae to 3 on
themodiﬁed Ashworth scale. The ﬁrst injection of botulinum toxin
is done in September 2012, he received 200 IU of Botox in each
surae triceps. Before a good result, three other botulinum toxin
injections with the same injection schedule are done out January
10, 20 September and 24 December 2013.
Mr D. is seen in consultation January 20, 2014 in a context of
tiredness, muscle weakness, and deﬁcit of shoulder and pelvic
girdles. Electromyography, made February 18, 2014, found
neurogenic traced in the deltoids. The whole of clinic and electrical
symptoms is strongly suggestive of a botulism-like syndrome. On
May 26, 2014 electromyogram is performed while the patient has
recovered its previous clinical condition. This is normal.
In the literature, few cases of botulism-like syndrome have been
described. The pathophysiologic exactmechanism remains unclear
[2]. Our patient developed the botulism-like syndrome in the
fourth injection so that the dose, dilution and injection technique
are the same. However, the interrogation conducted as a result of
this event is the notion of signiﬁcant tiredness after the third
injection without that he made the link with the injection. This
shows the importance of information and education of our patients
as part of repeated injections of botulinum toxin.
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Introduction After 30 years of use of intrathecal baclofen for the
treatment of generalized spasticity, no other treatment has
demonstrated superior efﬁciency. This long duration allows us
to study the real use of this treatment and its complications.
Method Retrospective study based on patient records.
Results The medical records of 45 patients were analysed: 27 are
still followed, 10 died, 4 stopped their treatment (9%), 4 were lost
to follow-up. The follow-up time was 7.3  4.9 years (0.6–
23.6 years), with an accumulated duration of 323 years. The causes
of spasticity included: spinal cord injury (15), multiple sclerosis (12),
cerebral palsy (4), stroke (4) traumatic brain injury (4) other (6). Six
could walk without assistance (FAC  4). In 24 the test trial was
realised by lumbar puncture and by external pump in 18. Fifty percent
had at least one signiﬁcant complication (between 1 and 10 events/
patient). On average, one signiﬁcant complication occurred every 7
years of follow-up. Sixty-seven percent of complications (31/46)were
related to the catheter: break (8), ﬁssure (6), disjunction (2), kinking
(1), migration (7), malposition (3) or unspeciﬁed dysfunction of
catheter (4). The remainder were related to infections (4), to skin
problems (3), rotation of the pump (3) and the problems of Baclofen
dosage (3). Few complications were related to pump dysfunction (1),
leaving aside cases of battery fading. The diagnosis of catheter ﬁssures
may be difﬁcult; it sometimes requires a scintigraphy and sometimes
a comparison test of the effect of a bolus by pump vs by lumbar
puncture.
Conclusion Despite a high rate of complications, treatment
discontinuation is rare, indicating good efﬁciency. The catheter
is much more frequently the cause of complications than the
pump. A detailed analysis of the surgical technique and a
prospective multicenter assessment of new catheters are needed.
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Introduction It’s in the wake of Brigitte Schurch’s work that the
indication of Botulinum Toxin (BoNT) developed in the treatment
of Detrusor Hyperactivity (DH).
DH treatment by BoNT injection is considered to be well tolerated.
However, in two patients treated with intradetrusor BoNT
injections, a motor deﬁcit located at the root of lower limbs was
noticed. That observation raises questions about its diffusion
beyond the injection site.
Observations They are two women with Secondary Progressive
Multiple Sclerosis (SPMS) receiving BoNT as a treatment for DH.
On several occasions in post injection, an aggravation of the proximal
motor deﬁcit on the hip ﬂexors was observed, which justiﬁed the
realization of a SOLUMEDROL bolus in the event of relapses.
Discussion Ramirez-Castaneda et al. [1] describe three means of
dissemination of the BoNT: migration by systemic or neuronal
transport, propagation and diffusion.
Migration by systemic transport: it has been established by
electromyography (EMG) analysis. These subclinical manifesta-
tions are not correlated by EMG [2]. This mechanism can’t account
for an isolated motor deﬁcit.
Migration by axonal transport Animal experiments conﬁrm the
axonal transport of BoNT. On human subjects, Marchand-Pauvert
et al. suggest its existence: reduction of the reciprocal inhibition
exercised by Renshaw cells after BoNT injections [3].
Local dissemination of BoNT by diffusion and propagation In the
absence of direct connection between the iliopsoas and the
bladder, this hypothesis looks compromised.
Synthesis A retrograde migration of BoNT via hypogastric nerves
seems to prevail. It could be followed by axonal anterograde
transport causing a deﬁcit on the hip ﬂexors via the L2 nerve root.
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